SCHEMBL26879302

SCHEMBL26879302

CC[C@H]1OC[C@@H](N2C(=O)C=CC2=O)[C@@H](OCc2ccccc2)[C@H]1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ BCHE P06276 2/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ PSEN1 P49768 4/20 0.34
▸ PSEN2 P49810 4/20 0.34
▸ APH1B Q8WW43 4/20 0.34
▸ NCSTN Q92542 4/20 0.34
▸ APH1A Q96BI3 4/20 0.34
▸ PSENEN Q9NZ42 4/20 0.34
▸ PDPK1 O15530 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CTSV O60911 1/20 0.33
▸ CTSL P07711 1/20 0.33
▸ CTSB P07858 1/20 0.33
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ CTSC P53634 1/20 0.33
▸ CTSF Q9UBX1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26879300 0.89 PSEN1 (0.39) MAPTCYP2C19BCHESLC6A2PSEN1
SCHEMBL26879312 0.88 GRM5 (0.35) MAPTCYP2C19BCHESLC6A2PDPK1
SCHEMBL26879331 0.84 BCHE (0.37) MAPTCYP2C19BCHESLC6A2PSEN1
SCHEMBL26879303 0.84 GSK3A (0.36) MAPTCYP2C19BCHESLC6A2PSEN1
SCHEMBL26879321 0.83 SLC6A2 (0.37) MAPTCYP2C19BCHESLC6A2PDPK1
SCHEMBL26879340 0.82 MAPT (0.36) MAPTCYP2C19BCHESLC6A2PSEN1
SCHEMBL26879283 0.81 NAAA (0.38) MAPTCYP2C19BCHESLC6A2PDPK1
SCHEMBL24256520 0.81 HTR1A (0.41) BCHESLC6A2
SCHEMBL26900842 0.81 HTR1A (0.41) BCHESLC6A2
SCHEMBL26879446 0.80 TACR1 (0.36) MAPTBCHESLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MAPT 4521/4885CYP2C19 4615/4885BCHE 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback